Brain morphologic changes in asymptomatic C9orf72 repeat expansion carriers

Neurology

Volumn 85, Issue 20, 2015, Pages 1780-1788

  Walhout, Renée ^a   Schmidt, Ruben ^a   Westeneng, Henk Jan ^a   Verstraete, Esther ^a   Seelen, Meinie ^a   Van Rheenen, Wouter ^a   De Reus, Marcel A ^a   Van Es, Michael A ^a   Hendrikse, Jeroen ^a   Veldink, Jan H ^a   Van Den Heuvel, Martijn P ^a   Van Den Berg, Leonard H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

REPETITIVE DNA; C9ORF72 PROTEIN, HUMAN; PROTEIN;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN; BRAIN SIZE; CONTROLLED STUDY; CORPUS CALLOSUM; CORTICAL THICKNESS (BRAIN); DIFFUSION WEIGHTED IMAGING; DISEASE CARRIER; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PYRAMIDAL TRACT; WHITE MATTER; AGED; ASYMPTOMATIC DISEASE; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; PATHOLOGY; PEDIGREE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ASYMPTOMATIC DISEASES; BRAIN; DIFFUSION MAGNETIC RESONANCE IMAGING; DNA REPEAT EXPANSION; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PROTEINS;

EID: 84947475419     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002135     Document Type: Article

References (40)

1. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003; 60: 1094-1097
2. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology 2005; 64: 1222-1226
3. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2012; 83: 102-108
4. van Rheenen W, van Blitterswijk M, Huisman MH, et al. Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology 2012; 79: 878-882
5. Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 323-330
6. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256
7. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257-268
8. Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. Lancet Neurol 2012; 11: 232-240
9. Bede P, Bokde AL, Byrne S, et al. Multiparametric MRI study of ALS stratified for the C9orf72 genotype. Neurology 2013; 81: 361-369
10. Mahoney CJ, Beck J, Rohrer JD, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012; 135: 736-750
11. Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 2012; 135: 693-708
12. Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012; 135: 794-806
13. Winkler AM, Kochunov P, Blangero J, et al. Cortical thickness or grey matter volume? The importance of selecting the phenotype for imaging genetics studies. Neuroimage 2010; 53: 1135-1146
14. Blokland GA, de Zubicaray GI, McMahon KL, Wright MJ. Genetic and environmental influences on neuroimaging phenotypes: a meta-analytical perspective on twin imaging studies. Twin Res Hum Genet 2012; 15: 351-371
15. Jahanshad N, Kochunov PV, Sprooten E, et al. Multi-site genetic analysis of diffusion images and voxelwise heritability analysis: a pilot project of the ENIGMA-DTI working group. Neuroimage 2013; 81: 455-469
16. van Blitterswijk M, van Es MA, Koppers M, et al. VAPB and C9orf72 mutations in 1 familial amyotrophic lateral sclerosis patient. Neurobiol Aging 2012; 33: 2950.e1-2950.e4
17. Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 9-14
18. Vazquez AI, Bates DM, Rosa GJ, Gianola D, Weigel KA. Technical note: an R package for fitting generalized linear mixed models in animal breeding. J Anim Sci 2010; 88: 497-504
19. Verstraete E, Veldink JH, Mandl RC, van Den Berg LH, van Den HeuvelMP. Impaired structural motor connectome in amyotrophic lateral sclerosis. PLoS One 2011; 6: e24239
20. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008; 131: 1540-1550
21. Vucic S, Winhammar JM, Rowe DB, Kiernan MC. Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clin Neurophysiol 2010; 121: 1781-1785
22. Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002; 73: 199-201
23. Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 2012; 135: 765-783
24. Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013; 12: 368-380
25. Niven E, Newton J, Foley J, et al. Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 172-179
26. Rohrer JD, Warren JD, Fox NC, Rossor MN. Presymptomatic studies in genetic frontotemporal dementia. Rev Neurol 2013; 169: 820-824
27. Dopper EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 2013; 80: 814-823
28. Dean DC III, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol 2014; 71: 11-22
29. Bede P, Elamin M, Byrne S, et al. Basal ganglia involvement in amyotrophic lateral sclerosis. Neurology 2013; 81: 2107-2115
30. Turner MR, Wicks P, Brownstein CA, et al. Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 853-854
31. Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry 2011; 82: 196-203
32. Rohrer JD, Nicholas JM, Cash DM, et al. Presymptomatic cognitive and neuroanatomical changes in Genetic Frontotemporal Dementia in the Genetic Frontotemporal Dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol 2015; 14: 253-262
33. Mackenzie IR, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014; 127: 347-357
34. Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013; 74: 20-38
35. Brettschneider J, Del Tredici K, Irwin DJ, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014; 127: 423-439
36. Tan RH, Devenney E, Dobson-Stone C, et al. Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS One 2014; 9: e105632
37. Bede P, Elamin M, Byrne S, et al. Patterns of cerebral and cerebellar white matter degeneration in ALS. J Neurol Neurosurg Psychiatry 2015; 86: 468-470
38. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a crosssectional cohort study. Lancet Neurol 2013; 12: 978-988
39. Simon NG, Turner MR, Vucic S, et al. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol 2014; 76: 643-657
40. Menke RA, Korner S, Filippini N, et al. Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis. Brain 2014; 137: 2546-2555